Abbott Overview. Investor Roadshow 2012

Size: px
Start display at page:

Download "Abbott Overview. Investor Roadshow 2012"

Transcription

1 Abbott Overview Investor Roadshow 2012

2 Forward-Looking Statement Some statements in this presentation may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995, including the planned separation of the research-based pharmaceutical company from the diversified medical products company and the expected financial results of the two companies after the separation. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward looking statements, and there is no assurance as to the timing of the planned separation or whether it will be completed. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors, to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2011, and in the interim reports filed on Form 10-Q for subsequent quarterly periods, and are incorporated by reference. Except as required by law, Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments. 2 Page 2 Investor Investor Roadshow Roadshow October Abbott Laboratories

3 Contents Separation Update Two New Investment Opportunities The New Abbott A Reliable Growth Investment Business Growth Drivers Established Pharmaceuticals Medical Devices Diagnostics Nutrition 3 Page 3 Investor Investor Roadshow Roadshow October Abbott Laboratories

4 Separation Update Separation on Track for Jan. 1, 2013 Debt and tender process expected to be completed in November When-issued trading begins in December On Jan. 2, 2013, Abbott and AbbVie trade regular way 4 Page 4 Investor Investor Roadshow Roadshow October Abbott Laboratories

5 Well Positioned as Independent Companies Shared Strengths; Distinct Identities Two large-cap, Fortune 200 healthcare investments with broad product portfolios, global scale, and strong financials, including healthy balance sheets and significant cash flow generation A large-cap diversified healthcare company driving performance across a broad portfolio of leading businesses aligned with favorable long-term healthcare and emerging market trends to generate top-tier growth, expanding margins and strong cash flow. A large-cap biopharmaceutical company with a number of differentiated growth brands, including a sustainable biologic, Humira, as well as a compelling pipeline. It generates robust, durable cash flow to drive shareholder returns supported by an attractive dividend. 5 Page 5 Investor Investor Roadshow Roadshow October Abbott Laboratories

6 Abbott Overview A Diversified Healthcare Products Leader

7 The New Abbott Evolving Portfolio of Growth Businesses One of the World s Most Successful Companies for More Than a Century Nutrition Diagnostics Medical Devices Established Pharmaceuticals Est. 50 yrs ago Est. 40 yrs ago Est. 20 yrs ago Est. 2 yrs ago Leadership in pediatric and adult Repositioned for profitable growth Innovation-driven medical devices Draws on Abbott s pharma heritage Science-based new product pipeline Customer-focused, efficient solutions Vascular, Diabetes, Vision Care Branded generics portfolio 7 Page 7 Investor Investor Roadshow Roadshow October Abbott Laboratories

8 The New Abbott Aligned with Favorable Healthcare Trends Increasing demand for healthcare and wellness due to rise in aging population and increasing incidence of chronic disease Growing and developing healthcare systems and improving socio-economic conditions in emerging markets Rewarding technology and innovation that creates more value for customers, patients and payors Abbott s businesses are leaders in their respective markets and are aligned with favorable long-term healthcare and emerging market trends to amplify growth opportunities 8 Page 8 Investor Investor Roadshow Roadshow October Abbott Laboratories

9 The New Abbott Growth Drivers Balanced Portfolio Abbott s diversity provides opportunities for reliable growth spanning geographies, businesses, products, customers and therapeutic areas Leadership Abbott holds leadership positions in product categories aligned with favorable demographics and healthcare trends in large and growing markets Innovation Abbott is developing transformational technologies and meaningful product iterations to improve the lives of consumers locally and globally Emerging Markets Abbott has the largest emerging market base of any diversified healthcare company, producing above-average growth Margin Expansion Abbott s portfolio of businesses are positioned to deliver earnings growth through gross and operating margin expansion 9 Page 9 Investor Investor Roadshow Roadshow October Abbott Laboratories

10 A Differentiated and Balanced Portfolio Strongly Positioned Among Industry Peers Leveraging the portfolio: Strategic track record Benefit of scale, both globally and locally Broad reputation and recognition of science and quality Seasoned management Financial discipline Established Pharma 2011 Sales: $5.4Bn Branded generics 60% emerging markets Diagnostics 2011 Sales: $4.2Bn Core Laboratory Molecular Point-of-Care Medical Devices 2011 Sales: $5.9Bn Vascular Vision Care Diabetes Care Nutrition 2011 Sales: $6.0Bn Pediatric Adult 40% emerging markets 10 Page 10 Investor Investor Roadshow Roadshow October Abbott Laboratories

11 Participating in Large Markets Where We Have Leadership Positions Diagnostics Nutrition $27B Market $36B Market #1 in Immunoassay Diagnostics #1 in Blood Screening Leading Point of Care Platform #1 WW Adult Nutrition #1 U.S. Pediatric Nutrition Leading science-based nutrition company Branded Generics $630B Market Leader in branded generics Strong positions in key emerging markets Medical Devices $30B Market #1 DES, #1 BMS, #1BVS #1 in LASIK; #2 in cataract Source: Company estimates. Current market positions. 11 Page 11 Investor Investor Roadshow Roadshow October Abbott Laboratories

12 Through Customer-Focused Innovation Pipeline Includes Dozens of Potentially Transformational Medical Technologies, Next-Generation Systems, New Formulations, Packaging and Brand Enhancements Nutrition Science-based pediatric and adult innovation in the areas of tolerance, cognition, immunity, inflammation, metabolism and lean body mass Diabetes: FreeStyle InsuLinx Easy-to-use touchscreen device for the insulin-using patient; also investing in next-generation sensing technology Established Pharmaceuticals New brands, adaptations, improved therapies, packaging and delivery solutions tailored to meet local and regional needs around the world Vision Care Multiple new products planned, including the Tecnis line of premium IOLs for cataracts Diagnostics Market-changing next-generation systems coupled with informatics and automation to deliver reliable results more efficiently Vascular: Absorb; MitraClip World s first bioresorbable vascular scaffold (BVS); percutaneous treatment for severe mitral regurgitation 12 Page 12 Investor Investor Roadshow Roadshow October Abbott Laboratories

13 An Increasing Emerging Market Presence Well Balanced Geographically with Significant Emerging Markets Presence United States: ~30% of sales Ex-U.S. Developed World: ~30% of sales Emerging Markets: ~40% of sales Emerging market sales targeted to approach 50% of sales by Page 13 Investor Investor Roadshow Roadshow October Abbott Laboratories

14 And Margin Expansion Potential Nutrition and Diagnostics Offer Most Opportunity for Margin Expansion Diagnostics Working to surpass previous target of 20% of sales by % of sales Nutrition Targeting >700bps of expansion by 2015 >20% of sales 8.0% of sales >13% of sales Diagnostics Operating Margin Nutrition Operating Margin 14 Page 14 Investor Investor Roadshow Roadshow October Abbott Laboratories

15 One of the Largest and Most Attractive Healthcare Investments Abbott: A Reliable Growth Investment Broad mix of global healthcare businesses in leadership positions Aligned with long-term healthcare and emerging market trends Well balanced and spread across geographies, including emerging markets New product pipeline includes game-changers and product evolution Generating significant cash flow; attractive dividend Gross and operating margin expansion opportunities Targeting industry-leading growth 15 Page 15 Investor Investor Roadshow Roadshow October Abbott Laboratories

16 The New Abbott 2013 Financial Profile* 2013 Sales ~ $23 billion, reflects mid-to-high-single-digit growth Gross margin ~ 55 percent (excludes non-cash amortization) R&D Between 6 and 7 percent of sales SG&A Net Interest Expense ~ 30 percent of sales Includes the Medical Device tax ~ $100 million Tax Rate ~21.5 percent Financial Strength Net Debt of $2.5 billion Significant operating cash flow of ~$4 billion 2013 annual dividend of $0.56 per share * As discussed on Abbott s 3Q12 earnings conference call Oct. 17, Page 16 Investor Investor Roadshow Roadshow October Abbott Laboratories

17 Established Pharmaceuticals Broad and Growing Portfolio of Branded Generics

18 Established Pharmaceuticals Broad and Growing Portfolio of Branded Generics Broad portfolio 500+ branded generic product portfolio Strong brand equity >50 percent of sales are self-pay Large commercial footprint Large sales force; distribution network Strong positions in emerging markets Manufacturing and supply expertise Driving efficiencies without compromising quality Development pipeline Development and Regulatory functions moving rapidly Hundreds of new product launches 60 Emerging Markets 2012 Sales Mix 40 Developed Markets 18 Page 18 Investor Investor Roadshow Roadshow October Abbott Laboratories

19 Established Pharmaceuticals Long-term Growth Strategies Increasing Breadth and Depth of Product Offerings Building on a broad and deep product portfolio Hundreds of brands worldwide Therapeutic areas of focus: Cardiovascular, Women s Health, Gastroenterology, Primary Care Launching new and improved formulations Registering products across multiple geographies Diverse product portfolio can be localized to market needs 19 Page 19 Investor Investor Roadshow Roadshow October Abbott Laboratories

20 Established Pharmaceuticals Long-term Growth Strategies Accelerating and Capturing New Sources of Growth Emerging markets becoming larger portion of EPD BRIC is >30% of sales, targeting mid to high teens growth Shift in global economy; emerging markets driving disproportionate healthcare spend Population growth; rising incomes Modernization of health systems; improving access to care Increased focus on treating chronic disease Higher out-of-pocket spend Emerging Markets 2012 Emerging Markets Page 20 Investor Investor Roadshow Roadshow October Abbott Laboratories

21 Medical Devices Driving Growth With Transformational Technology

22 Medical Devices Long-term Growth Strategies Diabetes and Vision Care: Driving Growth Through New Technology and Expansion in Emerging Markets Diabetes Care Advancing new product pipeline to address unmet testing needs of insulin-users FreeStyle InsuLinx launching broadly; followed by next-gen FreeStyle Precision product Investing in next-gen sensing technology Margin improvement driven by patient mix; cost reductions Vision Care #1 in LASIK, #2 in cataract/iol implant segment Cataract is largest, most profitable and fastest growing segment Cataract surgery: #1 surgical procedure done WW Developing new technologies to drive share, including new products targeted for fast-growing emerging markets 22 Page 22 Investor Investor Roadshow Roadshow October Abbott Laboratories

23 Medical Devices Long-term Growth Strategies Vascular Care: Driving Growth Through New Technology and Expansion in Emerging Markets Leadership Positions #1 Coronary Intervention Company #1 drug-eluting stent brand #1 metallic stent brand #1 coronary guide wires World s only BVS Expanding Leadership Across Business Segments Coronary Xience Xpedition Absorb bioresorbable vascular scaffold Structural Heart MitraClip device for mitral regurgitation Endovascular Numerous new products and indications Emerging market growth opportunities >20 percent of sales, growing 20% 23 Page 23 Investor Investor Roadshow Roadshow October Abbott Laboratories

24 Medical Devices Robust Vascular Pipeline: Absorb Absorb is the Next Generation in Treating Coronary Artery Disease Revolution 1 Balloon Angioplasty (PTCA) Revolution 2 Bare Metal Stents (BMS) Revolution 3 Drug-Eluting Stents (DES) Revolution 4 Absorb launching in Europe, Asia and Latin America Revascularization 0-3 months Restoration 4 mos-1 year Resorption after ~ 2 years Restore flow Restore natural vessel structure Restore vessel function 24 Page 24 Investor Investor Roadshow Roadshow October Abbott Laboratories

25 Medical Devices Robust Vascular Pipeline: MitraClip Mitral Regurgitation Significantly Undertreated Today Current patient population Affects 8 million people in the U.S. and Europe Causes chronic heart failure, stroke death Open-heart surgery currently only effective option in U.S. Medication treats symptoms; doesn t stop disease progression Majority of patients undertreated Only 50,000 mitral valve surgeries/year in U.S. Many MR patients are high-risk/not surgical candidates Due to invasiveness of surgery, many patients not referred MitraClip is a new treatment option Available in Europe and other international markets Under U.S. FDA review Clinical data demonstrates Favorable safety profile Measurable clinical and quality of life benefits Strong benefits in patients at high surgical risk and who have no other treatment alternatives Mitral Regurgitation MitraClip Profile 25 Page 25 Investor Investor Roadshow Roadshow October Abbott Laboratories

26 Diagnostics Leveraging Leadership Positions

27 Diagnostics Leveraging Leadership Positions Diagnostics Global Sales Mix Core Laboratory Point of Care Molecular Core Laboratory #1 in immunoassay #1 in blood screening Gaining share through placement of total solutions globally Next-generation systems in development Molecular and Point of Care Increasing penetration of systems, tests Capturing growth in emerging markets Leading Point of Care platform 27 Page 27 Investor Investor Roadshow Roadshow October Abbott Laboratories

28 Diagnostics Long-term Growth Strategies Core Laboratory: Expanding in Key Emerging Markets IVD Market Size: growing 4-5 percent globally Developed Markets Developed China Markets China Brazil Brazil Russia ~23% ~$700MM of sales ~$400MM ~$1.7Bn ~$14.6Bn >18% Favorable of sales Market Dynamics Diagnostics <5 percent of hospital costs; drive majority of decisions Healthcare spending rapidly increasing Accelerated demand for IVD products and patient populations Increased awareness of health and disease prevention Market Growth % 20% 10% 6% Sources: external sources and company estimates 28 Page 28 Investor Investor Roadshow Roadshow October Abbott Laboratories

29 Diagnostics Long-term Growth Strategies Reinvesting in R&D to Accelerate Sales Growth Next generation instruments and advanced technologies Informatics to help labs manage and retrieve vast amounts of data Enhancements of assay and detection systems New biomarkers and infectious disease diagnostics Gene-based oncology tests for targeted therapeutics 29 Page 29 Investor Investor Roadshow Roadshow October Abbott Laboratories

30 Diagnostics Consistently Delivering Margin Improvement Historical Margin Improvement Operating Margin Expansion % of Diagnostics Sales 18.6% 14.7% 8.0% 10.5% 11.3% Delivered >1000 basis points of improvement in operating margin over the last 5 years Page 30 Investor Investor Roadshow Roadshow October Abbott Laboratories

31 Diagnostics Expect Continued Margin Improvement Targeted Diagnostics Operating Margin >18% of sales >20% of sales Operating Margin Expectations Doubled dollar operating margin contribution from 2007 to 2011 Working to nearly double it again over the next 5 years Page 31 Investor Investor Roadshow Roadshow October Abbott Laboratories

32 Nutrition Attractive Profile and Compelling Growth Opportunity

33 Nutrition Attractive Profile; Compelling Growth Opportunity Participating in large and growing markets with favorable demographics and economics Aging population (50+) to triple globally by 2050 Emerging market birth rates continue to be high 70 percent increase in emerging market middle income households between 2010 and 2015 Growing awareness of nutrition/wellness Numerous leadership positions Significant cash flow generation High return on invested capital Global Nutrition Market $52Bn $36Bn Well Positioned to Capitalize on Industry Fundamentals Through Share Gains, New Products and Line Extensions Sources: Euromonitor, Nielsen, IMS and company estimates. 33 Page 33 Investor Investor Roadshow Roadshow October Abbott Laboratories

34 Nutrition #1 Nutrition Company Worldwide Leadership Sales Mix Global Nutrition #1 or #2 in 25 countries Leadership for majority of categories 50 consumer brands; 100 countries Pediatric 53 Pediatric Nutrition #1 in the U.S. Adult Adult Nutrition #1 in the U.S. #1 worldwide 47 #1 based on the adult and pediatric markets in which Abbott competes 34 Page 34 Investor Investor Roadshow Roadshow October Abbott Laboratories

35 Nutrition Long-term Growth Strategies Building product portfolio with steady rhythm of science-based new-product launches Expect to add >$1Bn in incremental sales from innovations in 2016 Expanding aggressively in key high-growth emerging markets 7 priority emerging markets driving majority of OUS growth Leveraging #1 global position in adult nutrition to grow, shape and further penetrate the market Meeting hospital needs of cost reduction while improving patient care Global Pediatric Nutrition Market $43Bn $30Bn Global Adult Nutrition Market $9Bn $6Bn Sources: Euromonitor, Nielsen, IMS and company estimates. 35 Page 35 Investor Investor Roadshow Roadshow October Abbott Laboratories

36 Nutrition Significantly Expand Operating Margin Nutrition Operating Margin: Targeting >700 basis points of expansion >13% of sales >20% of sales Margin Improvement Initiatives Product Materials & Packaging Manufacturing Processes & Plant Locations Supply Chain & Distribution Product & Market Rationalization Page 36 Investor Investor Roadshow Roadshow October Abbott Laboratories

37 New Abbott: An Attractive Healthcare Investment Majority of businesses in leadership positions aligned with favorable healthcare trends Well balanced geographically with a large emerging markets presence Maintaining financial heritage with robust cash flow generation and significant opportunity for further operating margin expansion One of the largest diversified healthcare products companies well positioned to deliver top-tier growth 37 Page 37 Investor Investor Roadshow Roadshow October Abbott Laboratories

38

Medical Devices. Driving Growth With Transformational Technology

Medical Devices. Driving Growth With Transformational Technology Medical Devices Driving Growth With Transformational Technology Forward-Looking Statement Some statements in this presentation may be forward-looking statements for purposes of the Private Securities Litigation

More information

Abbott Diagnostics. Durable Growth Business

Abbott Diagnostics. Durable Growth Business Abbott Diagnostics Durable Growth Business Forward-Looking Statement Some statements in this presentation may be forward-looking statements for purposes of the Private Securities Litigation Reform Act

More information

Abbott Nutrition. Attractive Profile and Compelling Growth Opportunities

Abbott Nutrition. Attractive Profile and Compelling Growth Opportunities Attractive Profile and Compelling Growth Opportunities Forward-Looking Statement Some statements in this presentation may be forward-looking statements for purposes of the Private Securities Litigation

More information

Emerging market opportunities for Roche. Luke Miels, Head of Asia-Pacific Roche Pharmaceuticals

Emerging market opportunities for Roche. Luke Miels, Head of Asia-Pacific Roche Pharmaceuticals Emerging market opportunities for Roche Luke Miels, Head of Asia-Pacific Roche Pharmaceuticals International region overview Eastern Europe & Middle East Asia Pacific Africa Latin America Market drivers

More information

2014 Wells Fargo Healthcare Conference June 17, 2014 NYSE: Q

2014 Wells Fargo Healthcare Conference June 17, 2014 NYSE: Q 2014 Wells Fargo Healthcare Conference June 17, 2014 NYSE: Q Copyright 2013 Quintiles Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains forward-looking statements

More information

A Leading Global Health Care Group

A Leading Global Health Care Group A Leading Global Health Care Group October 2016 Frankfurt stock exchange: FRE US ADR program: FSNUY www.fresenius.com/investors Safe Harbor Statement This presentation contains forward-looking statements

More information

SAMPLE. Asia-Pacific Interventional Cardiology Procedures Outlook to 2020. Reference Code: GDMECR0061PDB. Publication Date: May 2014

SAMPLE. Asia-Pacific Interventional Cardiology Procedures Outlook to 2020. Reference Code: GDMECR0061PDB. Publication Date: May 2014 Asia-Pacific Interventional Cardiology Procedures Outlook to 2020 Reference Code: GDMECR0061PDB Publication Date: May 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2

More information

St. Jude Medical J. P. Morgan 2010 Health Care Conference. Daniel J. Starks, Chairman, President and Chief Executive Officer January 11, 2010

St. Jude Medical J. P. Morgan 2010 Health Care Conference. Daniel J. Starks, Chairman, President and Chief Executive Officer January 11, 2010 St. Jude Medical J. P. Morgan 2010 Health Care Conference Daniel J. Starks, Chairman, President and Chief Executive Officer January 11, 2010 1 Forward-Looking Statements The following presentation contains

More information

McKesson Corporation J.P. Morgan Healthcare Conference

McKesson Corporation J.P. Morgan Healthcare Conference McKesson Corporation J.P. Morgan Healthcare Conference John Hammergren Chairman and Chief Executive Officer January 13, 2015 Forward-Looking Statements Some of the information in this presentation is not

More information

Enhancing Value With Financial & Operational Excellence

Enhancing Value With Financial & Operational Excellence Enhancing Value With Financial & Operational Excellence Robert Hombach CFO & COO Enhancing Value With Financial & Operational Excellence Growing Sales & Earnings Generating value in attractive markets

More information

Life Science - a sustainable platform for profitable growth

Life Science - a sustainable platform for profitable growth Life Science - a sustainable platform for profitable growth 2012 Life Science Information Day Bernd Reckmann Member of the Executive Board and Head of Chemicals Molsheim, France - December 5, 2012 Agenda

More information

Health Care Worldwide. Citi - European Credit Conference September 24, 2015 - London

Health Care Worldwide. Citi - European Credit Conference September 24, 2015 - London Health Care Worldwide Citi - European Credit Conference September 24, 2015 - London Safe Harbor Statement This presentation contains forward-looking statements that are subject to various risks and uncertainties.

More information

AXA INVESTMENT MANAGERS

AXA INVESTMENT MANAGERS AXA INVESTMENT MANAGERS Entering a new phase of growth Investor Day November 20, 2014 Andrea ROSSI CEO AXA Investment Managers Member of the AXA Group Executive Committee Certain statements contained herein

More information

Abbott to Acquire Alere, Becoming Leader in Point of Care Testing and Significantly Advancing Global Diagnostics Presence

Abbott to Acquire Alere, Becoming Leader in Point of Care Testing and Significantly Advancing Global Diagnostics Presence News Release Abbott to Acquire Alere, Becoming Leader in Point of Care Testing and Significantly Advancing Global Diagnostics Presence ABBOTT GAINS LEADERSHIP IN THE $5.5 BILLION POINT OF CARE SEGMENT,

More information

Cautionary Statement: Statements about the expected timing, financial impact and effects of the proposed transaction, and other statements in this

Cautionary Statement: Statements about the expected timing, financial impact and effects of the proposed transaction, and other statements in this Atmel Acquisition January 19, 2016 Cautionary Statement: Statements about the expected timing, financial impact and effects of the proposed transaction, and other statements in this presentation that are

More information

2002 Salomon Smith Barney Healthcare Conference. October 29, 2002

2002 Salomon Smith Barney Healthcare Conference. October 29, 2002 2002 Salomon Smith Barney Healthcare Conference October 29, 2002 John Hammergren Chairman and Chief Executive Officer Safe Harbor Clause Some of the information in this presentation may constitute forward-looking

More information

Global Industrials Conference GE Healthcare

Global Industrials Conference GE Healthcare Global Industrials Conference GE Healthcare John Dineen President & CEO March 18, 2014 Imagination at work. Caution Concerning Forward-Looking Statements: This document contains forward-looking statements

More information

A LEADING GLOBAL HEALTHCARE COMPANY

A LEADING GLOBAL HEALTHCARE COMPANY A LEADING GLOBAL HEALTHCARE COMPANY Roadshow Boston March 2, 2016 Frankfurt stock exchange (DAX30): FRE US ADR program (OTC): FSNUY www.fresenius.com/investors SAFE HARBOR STATEMENT This presentation contains

More information

STRATEGY UPDATE 2 MARCH 2016

STRATEGY UPDATE 2 MARCH 2016 STRATEGY UPDATE 2 MARCH 2016 Portfolio Focus on Attractive Growth and Margin Opportunities André Lacroix, CEO Intertek Group plc, is today announcing a strategic update outlining the Group s plan to deliver

More information

H1 2014 Earning Results JULY 30 TH, 2014

H1 2014 Earning Results JULY 30 TH, 2014 H1 2014 Earning Results JULY 30 TH, 2014 Disclaimer This document includes forward looking statements relating to Ingenico Group s future prospects, development and business strategies. By their nature,

More information

A LEADING GLOBAL HEALTH CARE GROUP. Frankfurt Stock Exchange (DAX30): FRE US ADR program (OTC): FSNUY wwww.fresenius.com/investors

A LEADING GLOBAL HEALTH CARE GROUP. Frankfurt Stock Exchange (DAX30): FRE US ADR program (OTC): FSNUY wwww.fresenius.com/investors A LEADING GLOBAL HEALTH CARE GROUP Frankfurt Stock Exchange (DAX30): FRE US ADR program (OTC): FSNUY wwww.fresenius.com/investors SAFE HARBOR STATEMENT This presentation contains forward-looking statements

More information

Health Care Worldwide

Health Care Worldwide Health Care Worldwide Credit Suisse Global Credit Products Conference September 18, 2014 Miami Credit Suisse Global Credit Products Conference, September 18, 2014 Copyright Page 1 Safe Harbor Statement

More information

J.P. Morgan Healthcare Conference 2014

J.P. Morgan Healthcare Conference 2014 January 13-16, 2014 J.P. Morgan Healthcare Conference 2014 Tecan Group AG Dr. David Martyr, CEO Safe Harbor Statement All statements in this presentation not referring to historical facts are predictions

More information

Health Care Worldwide

Health Care Worldwide Health Care Worldwide Goldman Sachs - Leveraged Finance Healthcare Conference March 4, 2014 New York Goldman Sachs Leveraged Finance Conference, Fresenius SE & Co. KGaA Copyright, March 4, 2014 Page 1

More information

J.P. Morgan 2016 Healthcare Conference CEO. January 12, 2016 NYSE: Q. Copyright 2016 Quintiles

J.P. Morgan 2016 Healthcare Conference CEO. January 12, 2016 NYSE: Q. Copyright 2016 Quintiles J.P. Morgan 2016 Healthcare Conference Tom Pike CEO January 12, 2016 Copyright 2016 Quintiles NYSE: Q Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains forward-looking

More information

Good morning and thank you for joining us to review UnitedHealth Group s third quarter results.

Good morning and thank you for joining us to review UnitedHealth Group s third quarter results. UnitedHealth Group Third Quarter 2015 Teleconference October 15, 2015 Good morning, I will be your conference facilitator today. Welcome to the UnitedHealth Group Third Quarter 2015 Earnings Conference

More information

Jefferies Global Healthcare Conference. Namal Nawana CEO and President. June 1, 2015 New York. Namal Nawana, CEO and President Alere Inc.

Jefferies Global Healthcare Conference. Namal Nawana CEO and President. June 1, 2015 New York. Namal Nawana, CEO and President Alere Inc. Jefferies Global Healthcare Conference June 1, 2015 New York Namal Nawana CEO and President Namal Nawana, CEO and President 2015 Alere Inc. Forward-Looking Statements This presentation contains forward-looking

More information

Acquisition of. Special Investor Presentation

Acquisition of. Special Investor Presentation Acquisition of Special Investor Presentation October 21, 2015 Forward-looking Statements This presentation contains statements which constitute forward-looking statements within the meaning of Section

More information

INSIDE INFORMATION ESTABLISHMENT OF JOINT VENTURE

INSIDE INFORMATION ESTABLISHMENT OF JOINT VENTURE Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness,

More information

Health Care Worldwide

Health Care Worldwide Health Care Worldwide Barclays European High Yield and Leveraged Finance Conference October 30, 2014 London Barclays European High Yield and Leveraged Finance Conference, October 30, 2014 Copyright Page

More information

Simon Dingemans Financial outlook and guidance

Simon Dingemans Financial outlook and guidance Simon Dingemans Financial outlook and guidance 6 May 2015 Novartis transaction accelerates our strategy and delivers against our financial objectives Better balanced and broader range of growth drivers

More information

A LEADING GLOBAL HEALTHCARE COMPANY

A LEADING GLOBAL HEALTHCARE COMPANY A LEADING GLOBAL HEALTHCARE COMPANY J.P. Morgan European Healthcare Conference June 23, 2016 Frankfurt stock exchange (DAX30): FRE US ADR program (OTC): FSNUY www.fresenius.com/investors SAFE HARBOR STATEMENT

More information

ACETO Corporation Investor Presentation November 2, 2016

ACETO Corporation Investor Presentation November 2, 2016 NASDAQ:ACET ACETO Corporation Investor Presentation November 2, 2016 Sourcing & Supplying Quality Products Worldwide Disclosure This presentation contains forward-looking statements, as defined by the

More information

Accenture Overview Page 1

Accenture Overview Page 1 Accenture Overview Page 1 Company Overview Accenture is one of the world s leading management consulting, technology services and outsourcing organizations, with more than 246,000 employees; offices and

More information

Unilever Q Results Graeme Pitkethly / Andrew Stephen April 14 th 2016

Unilever Q Results Graeme Pitkethly / Andrew Stephen April 14 th 2016 Unilever Q1 2016 Results Graeme Pitkethly / Andrew Stephen April 14 th 2016 SAFE HARBOUR STATEMENT This announcement may contain forward-looking statements, including forward-looking statements within

More information

Philips Healthcare overview. Steve Rusckowski CEO Philips Healthcare

Philips Healthcare overview. Steve Rusckowski CEO Philips Healthcare Philips Healthcare overview Steve Rusckowski CEO Philips Healthcare 1 Executive summary Exited 2010 with solid growth and strengthened operational performance as promised Grew faster than our markets,

More information

Philips Healthcare overview. Deborah DiSanzo, CEO Philips Healthcare

Philips Healthcare overview. Deborah DiSanzo, CEO Philips Healthcare Philips Healthcare overview Deborah DiSanzo, CEO Philips Healthcare Our focus Accelerate profitable growth Create value through solutions, clinical and business innovations Improve operational excellence

More information

Life & Protection. Scott Ham CEO. John Hunter COO. Analyst & Investor Conference

Life & Protection. Scott Ham CEO. John Hunter COO. Analyst & Investor Conference Life & Protection Scott Ham CEO John Hunter COO Analyst & Investor Conference New York City, December 2010 Key messages Grow profitable new sales Leverage expertise to increase recruiting and expand existing

More information

OraSure Technologies, Inc. Jefferies 2015 Global Healthcare Conference

OraSure Technologies, Inc. Jefferies 2015 Global Healthcare Conference OraSure Technologies, Inc. Jefferies 2015 Global Healthcare Conference Forward-Looking Statements These slides and the associated presentation contain certain forward-looking statements, including statements

More information

SAP The World s Leading Business Software Company. Rainer Zinow, Senior Vice President SAP Cloud, SAP SE Frankfurt am Main, September 9, 2014

SAP The World s Leading Business Software Company. Rainer Zinow, Senior Vice President SAP Cloud, SAP SE Frankfurt am Main, September 9, 2014 SAP The World s Leading Business Software Company Rainer Zinow, Senior Vice President SAP Cloud, SAP SE Frankfurt am Main, September 9, 2014 Safe Harbor Statement Any statements contained in this document

More information

I will now explain the results from the 2 nd quarter and first half of fiscal year ending March, 2014.

I will now explain the results from the 2 nd quarter and first half of fiscal year ending March, 2014. I will now explain the results from the 2 nd quarter and first half of fiscal year ending March, 2014. First, let me go over the highlights from the first half results. Due to factors including the weak

More information

Novartis: transforming our company for the future market

Novartis: transforming our company for the future market Novartis: transforming our company for the future market Joe Jimenez CEO Novartis JP Morgan Conference San Francisco January 12, 2015 Disclaimer This presentation contains forward-looking statements that

More information

2012 Letter from Our Chief Executive Officer

2012 Letter from Our Chief Executive Officer 2012 Letter from Our Chief Executive Officer Our strong performance in fiscal 2012 demonstrates that our growth strategy enabled us to further differentiate Accenture in the marketplace and deliver significant

More information

Pfizer Emerging Markets. Jean-Michel Halfon President and General Manager May 26, 2010

Pfizer Emerging Markets. Jean-Michel Halfon President and General Manager May 26, 2010 Pfizer Emerging Markets Jean-Michel Halfon President and General Manager May 26, 2010 Forward-Looking Statements and Non-GAAP Financial Information Our discussions during this presentation will include

More information

Cegedim Half-year results 2009 September 2009

Cegedim Half-year results 2009 September 2009 Cegedim Half-year results 2009 September 2009 1 Cegedim : Healthcare - its primary market Cegedim Founded in 1969 by Jean-Claude Labrune Jean-Claude Labrune family hold 67 % of Cegedim through FCB 849

More information

China Pharma Holdings, Inc. Reports Second Quarter 2010 Financial Results

China Pharma Holdings, Inc. Reports Second Quarter 2010 Financial Results China Pharma Holdings, Inc. Reports Second Quarter 2010 Financial Results HAIKOU CITY, China, August 10, 2010 China Pharma Holdings, Inc. (NYSE AMEX: CPHI) ( China Pharma or the Company ), a leading fully

More information

Ipsen Jefferies Healthcare Conference

Ipsen Jefferies Healthcare Conference Ipsen Jefferies Healthcare Conference November 2015 IPSEN pour nom de la société - 07/04/2011 / page 1 Disclaimer This presentation includes only summary information and does not purport to be comprehensive.

More information

Leading Intimate Healthcare. Lars Rasmussen, CEO

Leading Intimate Healthcare. Lars Rasmussen, CEO Leading Intimate Healthcare Lars Rasmussen, CEO Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not

More information

THE 2009 ANNUAL AMBULATORY SURGICAL TREATMENT CENTER QUESTIONNAIRE. 24-29 Definitions

THE 2009 ANNUAL AMBULATORY SURGICAL TREATMENT CENTER QUESTIONNAIRE. 24-29 Definitions THE 2009 ANNUAL AMBULATORY SURGICAL TREATMENT CENTER QUESTIONNAIRE Page Number P1-P2 Preface 3 22 Questionnaire Form 23 Charity Care Worksheet 24-29 Definitions PREFACE TO THE 2009 ANNUAL AMBULATORY SURGICAL

More information

GE Capital, Corporate Finance

GE Capital, Corporate Finance GE Capital, Corporate Finance Tom Quindlen Vertical Research Partners Industrial Conference September 9, 2013 Caution Concerning Forward-Looking Statements: This document contains forward-looking statements

More information

GE 2014 third quarter performance

GE 2014 third quarter performance GE 2014 third quarter performance Financial results & Company highlights October 17, 2014 Forward-Looking Statements: This document contains forward-looking statements that is, statements related to future,

More information

Telecom Italia Group CARLO BUORA. Executive Deputy Chairman

Telecom Italia Group CARLO BUORA. Executive Deputy Chairman Telecom Italia Group CARLO BUORA Executive Deputy Chairman Safe Harbour This presentation contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation

More information

J.P. MORGAN HEALTHCARE CONFERENCE

J.P. MORGAN HEALTHCARE CONFERENCE J.P. MORGAN HEALTHCARE CONFERENCE Bill Chase, Executive Vice President, Finance and CFO January 14, 2015 Disclaimer and Forward Looking Statement This presentation and its contents are confidential and

More information

Driving delivery, Driving change. Michael Polk, President & Chief Executive Officer

Driving delivery, Driving change. Michael Polk, President & Chief Executive Officer Driving delivery, Driving change Michael Polk, President & Chief Executive Officer Forward Looking Statement This presentation includes forward looking statements. Forward-looking statements are not guarantees

More information

A Leader in Medication Management and Patient Safety. March 17, 2015

A Leader in Medication Management and Patient Safety. March 17, 2015 A Leader in Medication Management and Patient Safety March 17, 2015 Disclaimers This slide presentation contains certain estimates and other forward-looking statements (as defined under Federal securities

More information

The New Mid-Term Plan (FY2013 FY2016)

The New Mid-Term Plan (FY2013 FY2016) The New Mid-Term Plan (FY2013 FY2016) Sustainable & Profitable Growth Terumo Corporation Executive Officer Strategy Planning Department Shouji Hatano 05.09.2013 Terumo Corporation Market Dynamics Slower

More information

Innovative genetics research and biomarker solutions to advance molecular medicine. Corporate Overview

Innovative genetics research and biomarker solutions to advance molecular medicine. Corporate Overview Innovative genetics research and biomarker solutions to advance molecular medicine Corporate Overview April 2013 1 Oxford Gene Technology (OGT) Advancing molecular medicine Well-established private genomics

More information

A Leading Global Health Care Group

A Leading Global Health Care Group A Leading Global Health Care Group Commerzbank German Investment Seminar January 11/12, 2016 For detailed financial information please see our annual/quarterly reports and/or conference call materials

More information

IMCD reports strong results for 2014

IMCD reports strong results for 2014 IMCD reports strong results for 2014 Rotterdam, The Netherlands 11 March 2015 - IMCD N.V. ( IMCD or Company ), a leading international speciality chemicals-focused distributor, today announces the 2014

More information

Pfizer Emerging Markets

Pfizer Emerging Markets Pfizer Emerging Markets Jean-Michel Halfon President and General Manager May 6, 2009 Forward-Looking Statements and Non-GAAP Financial Information Our discussions during this presentation will include

More information

Emerging Markets. Ronald de Jong CEO Emerging Markets

Emerging Markets. Ronald de Jong CEO Emerging Markets Growth in New Markets: Emerging Markets Ronald de Jong CEO Emerging Markets In 2009 we delivered on our commitment and delivered a third consecutive year of double digit growth for key Healthcare Emerging

More information

Ipsen. J.P. Morgan European Healthcare Conference. Thursday, June 26 th. IPSEN pour nom de la société - 07/04/2011 / page 1

Ipsen. J.P. Morgan European Healthcare Conference. Thursday, June 26 th. IPSEN pour nom de la société - 07/04/2011 / page 1 Ipsen J.P. Morgan European Healthcare Conference Thursday, June 26 th IPSEN pour nom de la société - 07/04/2011 / page 1 Disclaimer This presentation includes only summary information and does not purport

More information

Home Healthcare Solutions. Don Spence CEO Home Healthcare Solutions Philips Healthcare

Home Healthcare Solutions. Don Spence CEO Home Healthcare Solutions Philips Healthcare Home Healthcare Solutions Don Spence CEO Home Healthcare Solutions Philips Healthcare The transformation of care in the home is required to address demographic changes The issues The consequences Our responses

More information

Development of the Client-Focused, Capital-Efficient Business Model

Development of the Client-Focused, Capital-Efficient Business Model Development of the Client-Focused, Capital-Efficient Business Model David Mathers, Chief Operating Officer, Investment Bank at the Goldman Sachs European Financials Conference, Madrid, June 10, 2010 Cautionary

More information

Q3 2015 Financial Results and Corporate Update. November 4, 2015

Q3 2015 Financial Results and Corporate Update. November 4, 2015 Q3 2015 Financial Results and Corporate Update November 4, 2015 Introductions and Forward- Looking Statements Silvia Taylor, SVP Investor Relations and Corporate Affairs Agenda Introductions and Forward-Looking

More information

Midwest Investment Conference

Midwest Investment Conference June 22 2016 Midwest Investment Conference Lee D. Rudow President and CEO Michael J. Tschiderer Chief Financial Officer 1 Safe Harbor Statement This presentation contains forward looking statements within

More information

Colliers International Group Inc. Investor Presentation

Colliers International Group Inc. Investor Presentation Colliers International Group Inc. Investor Presentation Basis of Presentation All amounts in millions of US Dollars unless otherwise noted. Adjusted EBITDA ( AEBITDA ) and Adjusted EPS ( AEPS ) are non-gaap

More information

Safe Harbor Provision

Safe Harbor Provision Q2 2015 Safe Harbor Provision In accordance with the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors

More information

A Leading Global Health Care Group

A Leading Global Health Care Group A Leading Global Health Care Group Credit Suisse Global Health Care Conference, March 4, 2015 For detailed financial information please see our annual/quarterly reports and/or conference call materials

More information

Company update. Frans van Houten, CEO Royal Philips

Company update. Frans van Houten, CEO Royal Philips Company update Frans van Houten, CEO Royal Philips 1 Key takeaways Accelerate! is working and we are committed to achieving our 2013 targets; on-going headwinds remain a concern We have actively restructured

More information

J.P. MORGAN HIGH YIELD & LEVERAGED FINANCE CONFERENCE FEBRUARY 24, 2015

J.P. MORGAN HIGH YIELD & LEVERAGED FINANCE CONFERENCE FEBRUARY 24, 2015 J.P. MORGAN HIGH YIELD & LEVERAGED FINANCE CONFERENCE FEBRUARY 24, 2015 DISCLAIMER This presentation contains, in addition to historical information, certain forward-looking statements within the meaning

More information

A Leading Global Health Care Group

A Leading Global Health Care Group A Leading Global Health Care Group JP Morgan Milan Investor Forum October 1, 2015 For detailed financial information please see our annual/quarterly reports and/or conference call materials on www.fresenius.com/ir.

More information

ClickSoftware Technologies Ltd. (NasdaqGS: CKSW) Company Presentation

ClickSoftware Technologies Ltd. (NasdaqGS: CKSW) Company Presentation ClickSoftware Technologies Ltd. (NasdaqGS: CKSW) Company Presentation Presentation Outline Company Overview Market and Leadership Position Customers and Partners The Need and Our Solution Return on Investment

More information

Goldman Sachs Presentation to Credit Suisse Financial Services Conference

Goldman Sachs Presentation to Credit Suisse Financial Services Conference Goldman Sachs Presentation to Credit Suisse Financial Services Conference Lloyd C. Blankfein Chairman and Chief Executive Officer February 0, 205 Cautionary Note on Forward-Looking Statements Today s presentation

More information

Paul Smit CA Chevreux, March 16, 2006 Paris

Paul Smit CA Chevreux, March 16, 2006 Paris Progress report Paul Smit CA Chevreux, March 16, 2006 Paris Forward Looking Statements Forward Looking Statements This document contains certain forward-looking statements with respect to the financial

More information

Contacts: Media: Margaret Kirch Cohen, +1 312-696-6383 or margaret.cohen@morningstar.com Investors may submit questions to investors@morningstar.com.

Contacts: Media: Margaret Kirch Cohen, +1 312-696-6383 or margaret.cohen@morningstar.com Investors may submit questions to investors@morningstar.com. Contacts: Media: Margaret Kirch Cohen, +1 312-696-6383 or margaret.cohen@morningstar.com Investors may submit questions to investors@morningstar.com. FOR IMMEDIATE RELEASE Morningstar, Inc. Reports First-Quarter

More information

MEDTRONIC, INC. WORLD WIDE REVENUE (Unaudited)

MEDTRONIC, INC. WORLD WIDE REVENUE (Unaudited) WORLD WIDE REVENUE ($ millions) 1 2 3 4 1 2 3 4 FY11 FY11 FY11 FY11 FY11 FY12 FY12 FY12 FY12 FY12 QTR 1 QTR 2 QTR 3 QTR 4 Total QTR 1 QTR 2 QTR 3 QTR 4 Total REPORTED REVENUE : CARDIAC RHYTHM DISEASE MANAGEMENT

More information

Taking Strategic Partnerships to the Next Level: An Alternative Approach to Licensing Your Development Asset

Taking Strategic Partnerships to the Next Level: An Alternative Approach to Licensing Your Development Asset Taking Strategic Partnerships to the Next Level: An Alternative Approach to Licensing Your Development Asset Introduction In this era of strategic development deals, inventiv Health has significantly broadened

More information

Emmanuel Babeau Deputy CEO, Finance & Legal

Emmanuel Babeau Deputy CEO, Finance & Legal Investor Day February 20, 2014 Group Finance Emmanuel Babeau Deputy CEO, Finance & Legal Disclaimer All forward-looking statements are Schneider Electric management s present expectations of future events

More information

Unilever First Half 2015 Results Paul Polman / Jean-Marc Huët 23 rd July 2015

Unilever First Half 2015 Results Paul Polman / Jean-Marc Huët 23 rd July 2015 Unilever First Half 2015 Results Paul Polman / Jean-Marc Huët 23 rd July 2015 SAFE HARBOUR STATEMENT This announcement may contain forward-looking statements, including forward-looking statements within

More information

VARIAN MEDICAL SYSTEMS JP Morgan Healthcare Conference -

VARIAN MEDICAL SYSTEMS JP Morgan Healthcare Conference - VARIAN MEDICAL SYSTEMS JP Morgan Healthcare Conference - Dow Wilson, CEO January 13, 2015 January 2015 2015 VARIAN MEDICAL SYSTEMS. ALL RIGHTS RESERVED. Forward-Looking Statements Forward-Looking Statements

More information

Careers in the Pharmaceutical Industry - what really counts - Dr. Wolfgang Haupt Novartis Vaccines & Diagnostics, Marburg, Germany

Careers in the Pharmaceutical Industry - what really counts - Dr. Wolfgang Haupt Novartis Vaccines & Diagnostics, Marburg, Germany Careers in the Pharmaceutical Industry - what really counts - Dr. Wolfgang Haupt Novartis Vaccines & Diagnostics, Marburg, Germany Agenda Section 1 Overview on the Top Ten Pharmaceutical Companies Section

More information

GSK. Simon Dingemans, CFO. Bank of America Healthcare Conference 19 th September 2014

GSK. Simon Dingemans, CFO. Bank of America Healthcare Conference 19 th September 2014 GSK Simon Dingemans, CFO Bank of America Healthcare Conference 19 th September 2014 GSK strategy is delivering Focus on innovation and portfolio optimisation to maximise returns Non US/EU sales: 26% in

More information

> Investor Presentation June 2016

> Investor Presentation June 2016 > Investor Presentation June 2016 These slides and accompanying oral presentation contain forward-looking statements. These statements relate to future events or to future financial performance and involve

More information

3 rd Quarter 2014 Earnings Conference Call Transcript

3 rd Quarter 2014 Earnings Conference Call Transcript 3 rd Quarter 2014 Earnings Conference Call Transcript Overview*: BDC reported 3Q14 consolidated revenues of $613.1M, income from continuing operations of $50.4M and diluted EPS from continuing operations

More information

Roper Technologies, Inc. Oppenheimer Industrial Growth Conference

Roper Technologies, Inc. Oppenheimer Industrial Growth Conference Roper Technologies, Inc. Oppenheimer Industrial Growth Conference May 10, 2016 Safe Harbor Statement The information provided in this presentation contains forward-looking statements within the meaning

More information

Midwest Investment Conference

Midwest Investment Conference NYSE MKT: EVBN www.evansbank.com Midwest Investment Conference June 22, 2016 David J. Nasca President & CEO John B. Connerton Senior Vice President & CFO Safe Harbor Statement This presentation includes

More information

First-Quarter 2014 Financial Results

First-Quarter 2014 Financial Results First-Quarter 2014 Financial Results www.unisys.com/investor Ed Coleman Chairman & CEO Janet Haugen SVP & CFO April 22, 2014 Disclaimer Statements made by Unisys during today's presentation that are not

More information

February 2014 Patient Savings Program Use Analysis

February 2014 Patient Savings Program Use Analysis Providing key policy setters and decision makers in the global health sector with unique and transformational insights into healthcare dynamics derived from granular analysis of information. February 2014

More information

GLOBAL BANKING & MARKETS

GLOBAL BANKING & MARKETS GLOBAL BANKING & MARKETS Investors Day Boadilla del Monte. September 14 th, 2007 Important information 2 Banco Santander, S.A. ("Santander") cautions that this presentation contains forward-looking statements

More information

ITW Conference Call Third Quarter 2013

ITW Conference Call Third Quarter 2013 ITW Conference Call Third Quarter 2013 October 22, 2013 SOLID GROWTH. STRONG RETURNS. BEST-IN-CLASS OPERATOR. Forward-Looking Statements Safe Harbor Statement This conference call contains forward-looking

More information

Strategic and Operational Overview May 11, 2016

Strategic and Operational Overview May 11, 2016 Strategic and Operational Overview May 11, 2016 Safe Harbor Statement This presentation contains several forward-looking statements. Forward-looking statements are those that use words such as believe,

More information

Wealth Management and Securities Services

Wealth Management and Securities Services U.S. Bancorp Investor Day Wealth Management and Securities Services Terry Dolan Vice Chairman September 12, 2013 # Forward-looking Statements and Additional Information The following information appears

More information

EDWARDS LIFESCIENCES REPORTS STRONG FIRST QUARTER RESULTS DRIVEN BY SALES GROWTH OF 18.8 PERCENT

EDWARDS LIFESCIENCES REPORTS STRONG FIRST QUARTER RESULTS DRIVEN BY SALES GROWTH OF 18.8 PERCENT Edwards Lifesciences Corporation One Edwards Way Irvine, CA USA 92614 Phone: 949.250.2500 Fax: 949.250.2525 www.edwards.com FOR IMMEDIATE RELEASE Media Contact: Amanda C. Fowler, 949-250-5070 Investor

More information

News Release. Zurich reports continued strong operating performance for the first six months of 2008

News Release. Zurich reports continued strong operating performance for the first six months of 2008 News Release Zurich reports continued strong operating performance for the first six months of 2008 Zurich Financial Services Mythenquai 2 8022 Zurich Switzerland www.zurich.com SWX Swiss Exchange/ SWX

More information

Wells Fargo Healthcare Conference

Wells Fargo Healthcare Conference Wells Fargo Healthcare Conference Dave Denton Executive Vice President & Chief Financial Officer June 18, 2014 Forward-looking Statements During today s presentation, we will make forward-looking statements

More information

Creating Value through Responsible Business

Creating Value through Responsible Business Corporate Responsibility Creating Value through Responsible Business ESG Investor Call Jürgen Brokatzky-Geiger, Global Head Corporate Responsibility Eric Cornut, Chief Ethics, Compliance & Policy Officer

More information

Comprehensive Medical Waste and Unused Medication Management Solutions Provider NASDAQ: SMED

Comprehensive Medical Waste and Unused Medication Management Solutions Provider NASDAQ: SMED Comprehensive Medical Waste and Unused Medication Management Solutions Provider NASDAQ: SMED INVESTOR PRESENTATION NOVEMBER Safe Harbor These slides contain (and the accompanying oral discussion will contain)

More information

Abbott Adding Value in Ireland. Investment in Ireland has been consistent and regionally spread with operations in all four provinces.

Abbott Adding Value in Ireland. Investment in Ireland has been consistent and regionally spread with operations in all four provinces. Abbott in Ireland Abbott Ireland Diabetes Care Donegal Abbott Nutrition Ltd. Sligo Abbott Ireland Diagnostics Division Sligo Abbott Ireland Nutrition Division & Abbott Ireland Manufacturing Operations

More information

Logista Q Results. February 9, 2016

Logista Q Results. February 9, 2016 Logista Q1 2016 Results February 9, 2016 Logista reports Q1 2016 Results Logista announces today its First Quarter Results for 2016. Main highlights: Revenues growing by 2.3% Good performance of Economic

More information